Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
Cobridge Co., Ltd.
Tokyo, Japan
We assist medical device companies with the medical device registration and approval in Japan. Regulatory consulting services and DMAH services for foreign manufacturers to enter Japanese market.
MDREX, Medical Device, Digital Health Consulting Group
Seoul, Republic of Korea (HQ), Japan Office
We offer total solutions for market entry in South Korea and global expansion (e.g., Japan, USA, Europe). Key areas include product approval, reimbursement listings (HIRA), and Quality System certification (KGMP). They are particularly strong in innovative products like SaMD, medical wearables, and 3D printing for medical use, and provide in-depth expertise in cybersecurity and clinical trial planning.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
January 6, 2026
Approximately 5 minutes
Considerations for Non-Clinical Studies in the Development of Diagnostic Radiopharmaceuticals in Japan
Considerations for Non-Clinical Studies in the Development of Diagnostic Radiopharmaceuticals in Japan (PMDA)
Why this document matters
PMDA issued an Early Consideration (March 26, 2025) to add practical clarification on what non-clinical studies are expected for diagnostic radiopharmaceuticals and when they should be conducted, building on Japan’s existing guideline for diagnostic radiopharmaceuticals and reflecting newer ICH thinking.
Core idea: tailor the non-clinical package to “diagnostic” use
Diagnostic radiopharmaceuticals often involve single administration and, in many cases, microdose-level total mass (including non-radioactive ingredients). PMDA’s key message is that requirements should be assessed case by case, with early PMDA consultation encouraged for agreement on the study plan.
1) Safety pharmacology: when microdose may change expectations
PMDA reiterates that, in principle, core battery safety pharmacology is expected before first-in-human studies, consistent with ICH safety pharmacology concepts. However, where the clinically recommended dose is within the microdose range, PMDA indicates the need for core battery studies (including safety pharmacology embedded in tox studies) should be evaluated case by case, and may be omitted if a convincing rationale demonstrates no meaningful impact on vital organ functions.
PMDA lists examples of information that can support the case-by-case decision:
- Pharmacological properties (on-/off-target, binding specificity/affinity, etc.)
- Existing non-clinical and clinical safety information
- Overseas clinical use experience
- Safety information from structurally related compounds (including different radionuclide labels)
2) ADME and drug–drug interactions: stepwise and proportionate
Even for diagnostic products, PMDA notes DDI information can be valuable for appropriate clinical use. The document points to a stepwise approach aligned with ICH DDI principles and timing expectations.
Key practical nuance from PMDA:
- If clinical use is single-dose and the product is rapidly eliminated, in vitro evaluation of enzyme induction potential is not necessarily required.
- For biologics used as diagnostic radiopharmaceuticals (e.g., radiolabeled monoclonal antibodies), PMDA highlights generally lower PK-DDI risk than small molecules and recommends evaluating interaction potential using factors such as pharmacological action, clearance, and likely concomitant medications (since standard in vitro methods for chemicals may not apply).
3) Toxicology: repeated-dose expectations, plus accepted alternatives
PMDA notes that, per the underlying guideline, a 4-week repeated-dose toxicity study in two species (rodent + non-rodent) is generally expected before a marketing authorization application—even if clinical use is single-dose and the mass is in the microdose range.
However, PMDA also describes scenarios where alternatives may be acceptable, such as:
- A shorter-duration repeated-dose study, or
- An extended single-dose toxicity study in one species (typically rodents),
when justified by evidence such as the absence of unexpected safety signals, overseas use experience, and relevant data on related compounds.
PMDA cautions that if repeated clinical dosing is planned, or if the compound is highly novel with off-target concerns, repeated-dose evaluation across multiple species becomes particularly important—and consultation with PMDA before finalizing a non-standard tox plan is strongly recommended.
4) Radiolytic products and impurities: apply ICH impurity principles
Radiolytic products may form between production and administration. PMDA states impurity safety (including radiolytic products) should be evaluated consistent with ICH impurity principles (e.g., Q3A/Q3B and M7), and mentions that non-clinical studies using a product with decayed radioactivity may be useful for assessing impurity safety.
Practical takeaways for developers
- Start with the diagnostic context (single use, microdose mass, rapid clearance) and build a proportionate plan.
- Justify omissions with structured evidence (pharmacology, prior data, overseas experience, related compounds).
- Use a stepwise DDI strategy, especially where clinical use or clearance profile suggests limited interaction potential.
- Treat radiolysis/impurities as a core CMC–nonclinical interface topic early, not an afterthought.
- Engage PMDA early to align on any streamlined package before committing to studies.
References (PDF)
Have a Question?
Ask our experts about this topic. We'll do our best to respond to your question.
Related Articles
Approximately 5 minutes
Points to Consider in Developing Drugs for Pediatric Inflammatory Bowel Disease in Japan
PMDA released points to consider for planning clinical studies in pediatric inflammatory bowel disease (IBD) drug development, aiming to improve availability of therapies for children by addressing pediatric-specific challenges.
Approximately 5 minutes
Points to Consider in the Clinical Development of Drugs for Transthyretin Amyloid Cardiomyopathy (Early Consideration) in Japan
This PMDA Early Consideration document outlines strategic clinical development points for transthyretin amyloid cardiomyopathy (ATTR-CM) drugs in Japan, including rare disease considerations, endpoint selection, trial design, and multi-regional development.
Approximately 5 minutes
Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance in Japan
This PMDA Early Consideration outlines key considerations for designing clinical trials to assess impacts of psychotropic drugs on driving performance, focusing on clinically meaningful driving impairment and appropriate evaluation methods.
Approximately 5 minutes
Japan Specialty Fulfillment for Medical Devices: Low Volume, High Value Sales
Specialty Fulfillment is a crucial service for foreign medical device manufacturers targeting low-volume, high-value sales in Japan, often utilizing an Independent License Holder to manage customs, storage, and distribution to maintain high profit margins.
Approximately 5 minutes
Points to Consider for the Design of Clinical Trials to Assess the Effects of Psychotropic Drugs on Driving Performance in Japan
This PMDA Early Consideration outlines key considerations for designing clinical trials to assess impacts of psychotropic drugs on driving performance, focusing on clinically meaningful driving impairment and appropriate evaluation methods.
Approximately 5 minutes
Guideline for Clinical Evaluation of Antibacterial Drugs in Japan
The PMDA’s *Guideline for Clinical Evaluation of Antibacterial Drugs* provides comprehensive principles for designing and conducting clinical studies of antibacterial drugs for regulatory approval, reflecting current scientific knowledge and global harmonization.
Approximately 5 minutes
Considerations for Non-clinical Studies of Combination Prescription Drugs with Similar Formulations in Japan
PMDA’s Early Consideration document clarifies how non-clinical pharmacology and toxicology studies should be approached for combination prescription drugs whose formulations are similar to approved products.
Approximately 5 minutes
Points to Consider for Clinical Development of Drugs Intended for Treatment of Psoriatic Arthritis in Japan
This PMDA Early Consideration outlines current regulatory thinking for clinical development of psoriatic arthritis (PsA) drugs in Japan, including disease characterization, endpoints, study design considerations, and use of global data.
Approximately 5 minutes
On Release of the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents in Japan
The *Guideline for Clinical Evaluation of Oral Hypoglycemic Agents* provides comprehensive procedures for planning, conducting, and evaluating clinical studies of oral hypoglycemic agents in Japan, focusing on glycemic control markers, safety evaluation, and inclusion of relevant patient populations.
Approximately 5 minutes
Considerations for Non-Clinical Studies in the Development of Diagnostic Radiopharmaceuticals in Japan
PMDA’s Early Consideration (Mar 26, 2025) explains when non-clinical packages for diagnostic radiopharmaceuticals can be streamlined (e.g., microdose), and how to address safety pharmacology, DDI/ADME, toxicity, and radiolytic impurities.
Approximately 5 minutes
Guideline for Clinical Evaluation of Diagnostic Radiopharmaceuticals in Japan
PMDA/MHLW’s guideline (PFSB/ELD Notification No. 0611-1) explains how to design non-clinical and clinical evidence for diagnostic radiopharmaceutical approval in Japan, emphasizing imaging accuracy, clinical significance, and radiation dosimetry.
Approximately 5 minutes
Checklist for Japan’s 30-day Clinical Trial Notification Review (Initial CTN, Oncology Drugs)
PMDA’s early-consideration checklist summarizes what reviewers expect to see in an initial CTN for oncology drugs—covering safety reporting workflows, Phase 1 population ethics, starting dose rationale, DLT/tolerability evaluation, informed consent essentials, and required attached documents.
Approximately 5 minutes
Statistical Considerations for Phase I Oncology Trials in Japan (Safety-focused Early Consideration)
PMDA’s early-consideration paper explains what statistical evidence and simulation outputs should support oncology Phase I dose-escalation designs in Japan’s 30-day CTN review, with emphasis on safety, termination behavior under excessive toxicity, and managing design modifications like backfilling or schedule changes.